Drugs.com
JUNE 15, 2024
SATURDAY, June 15, 2024 -- Summertime is primetime for the great outdoors, but that can mean new hazards for your eyes, one expert warned. Simple steps can help cut the risk, said ophthalmologist Dr. Masih Ahmed, an assistant professor of.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for ABILIFY+MYCITE+KIT Abilify Mycite Kit is a drug marketed by Otsuka and is included in one NDA. It is available from one supplier.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for BALVERSA Balversa is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for PARSABIV Parsabiv is a drug marketed by Kai Pharms Inc and is included in one NDA. It is available from one supplier.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for ERLEADA Erleada is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for REXULTI Rexulti is a drug marketed by Otsuka and is included in one NDA. It is available from two suppliers.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for DUOBRII Duobrii is a drug marketed by Bausch and is included in one NDA. It is available from one supplier.
Drug Patent Watch
JUNE 15, 2024
Annual Drug Patent Expirations for BRYHALI Bryhali is a drug marketed by Bausch and is included in one NDA. It is available from one supplier.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
JUNE 15, 2024
This chart shows the pharmaceutical companies with the most patents in New Zealand.
Expert insights. Personalized for you.
75 
Let's personalize your content